 |
|
|
| |
Safety and Efficacy of Oral TLR8 Agonist Selgantolimod in Viremic Adult Patients With Chronic Hepatitis B
|
| |
| |
EASL International Liver Congress, June 23-26, 2021
Harry L. Janssen,1 Young-Suk Lim,2 Hyung Joon Kim,3 Cheng-Hao Tseng,4 Carla Coffin,5 Magdy Elkashab,6 Sang Hoon Anh,7 Anh-Hoa Nguyen,8 Diana Chen,8 Jeff Wallin,8
Susanna K. Tan,8 Jenny C. Yang,8 Anuj Gaggar,8 Diana M. Brainard,8 Scott Fung,1 Yoon Jun Kim,9 Jia-Horng Kao,10 Wan-Long Chuang,11 Anna E. Brooks,12 P. Rod Dunbar12
1Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; 2Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; 3Chung-Ang University College of Medicine, Seoul; 4E-Da Hospital, Kaohsiung City, Taiwan; 5Cumming School of Medicine, University of Calgary, Alberta, Canada; 6Toronto Liver Centre, Toronto; 7Severance Hospital, Yonsei University College of Medicine, Seoul; 8Gilead Sciences, Inc., Foster City, California, USA; 9Seoul National University Hospital, Seoul; 10National Taiwan University Hospital, Taipei City, Taiwan; 11Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City; 12School of Biological Sciences, Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, New Zealand
|
| |
|
|
|
|
|
